MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma
This study demonstrated the development of a novel CAR-T therapy for mucosal melanoma, MUC18 CAR-T, that showed strong potency in tumor eradication and inhibition of tumor relapse. This candidate CAR-T therapy could provide a promising strategy for the treatment of the refractory melanoma.
Authors
- Kaiping Liu (ORCID: https://orcid.org/0000-0003-1962-9979)
- Mengmeng Liang
- Qian Guo (ORCID: https://orcid.org/0000-0002-1211-6436)
- Fenghao Zhang (ORCID: https://orcid.org/0000-0002-5405-590X)
- Xun Meng (ORCID: https://orcid.org/0000-0001-9590-6670)
- Shu-Hui Liu (ORCID: https://orcid.org/0000-0002-5221-6853)
- Yan Kong (ORCID: https://orcid.org/0000-0002-2266-7872)
- Feng Shi (ORCID: https://orcid.org/0000-0002-1969-5493)
- Haizhen Du
- Qiaozhen Li
- Yanfang Tang (ORCID: https://orcid.org/0009-0008-9991-9485)
- Lihua Wang (ORCID: https://orcid.org/0000-0002-1461-0438)
- Xin‐an Lu (ORCID: https://orcid.org/0000-0003-4721-1684)
- Jing Shi
- Ting He
- Yanping Ding
Institutions
- MultiCare Health System (US)
- Peking University (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- Peking University Cancer Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s12967-025-06365-x
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China